REKOM BIOTECH signs a Singapure and Indonesia distribution agreement

8/2/2022

New distribution partnership with AFIRMUS

Rekom Biotech is delighted to announce that we have just started a new distribution partnership with Afirmus Biosource. From now on, our customers from Singapore and Indonesia will be able to purchase our IVD raw materials with the assistance of our new partner.

(...)

View more

CATEGORY: NEWS

REKOM BIOTECH signs a Japan distribution agreement

7/27/2022

New distribution partnership with FILGEN

Rekom Biotech is pleased to announce that we have just started a new distribution partnership with Filgen Inc. From now on, our Japanese customers will be able to purchase our IVD raw materials through our new partner.

(...)

View more

CATEGORY: NEWS

REKOM BIOTECH signs a South Korea distribution agreement

6/1/2022

New distribution partnership with MORE BIO

We keep growing! Rekom Biotech is pleased to announce that we have just started a new distribution partnership with MoreBio Co., Ltd. From now on, MoreBio will be the responsible company supervising the distribution of our IVD reagents in the Republic of Korea.

(...)

View more

CATEGORY: NEWS

The IDEA Agency grants Rekom Biotech an incentive to develop new recombinant antigens for the detection of Dengue

10/14/2021

Idea Dengue

The Andalusian Agency for Innovation and Development IDEA, of the Junta de Andalucía, has resolved a grant of subsidies, under a competitive competition regime, to industrial research projects and experimental development projects in Andalusia, 80% co-financed by the European Union through the European Regional Development Fund, FEDER.

(...)

View more

CATEGORY: NEWS

REKOM BIOTECH signs a distribution agreement for United Kingdom and Ireland

7/27/2021

2B Scientific Agreement

We are pleased to announce our new distribution partnership with 2B Scientific Ltd. On July 27th, our company sealed an exclusive distribution agreement for the commercialization of our products throughout the United Kingdom and Ireland.

(...)

View more

CATEGORY: NEWS